A review of preclinical evidence found multiple non-intoxicating cannabinoids (beyond CBD) can reduce gut motility, inflammation, and abdominal pain through non-CB receptor mechanisms, including TRP and voltage-gated ion channels.
Gastroenterologists, pain researchers, and IBD patients interested in cannabinoid therapies
Non-intoxicating cannabinoids work through multiple non-CB receptor mechanisms
What the researchers found
Non-intoxicating cannabinoids (niCBs) show potential to normalize intestinal motility, reduce inflammation, and produce analgesic effects in preclinical models of visceral pain. Many of these effects are not mediated through classical CB1/CB2 receptors but rather through TRP channels and voltage-gated ion channels. Evidence also suggests niCBs can be combined for enhanced potency (entourage effect).
Why it matters
Patients with inflammatory bowel diseases increasingly use cannabis for abdominal pain, but clinical results have been mixed. This review suggests the focus on THC and CBD may be too narrow, and that other non-intoxicating cannabinoids acting through different mechanisms may be more relevant for gut pain.
The numbers in context
Multiple niCBs reviewed beyond CBD. Three main mechanism categories: TRP channel modulation, voltage-gated ion channel effects, and non-CB receptor activity. Evidence for combination effects (entourage) among niCBs.
How the study worked
Review of preclinical data on non-intoxicating cannabinoids in the treatment of abdominal pain, with focus on non-CB receptor mechanisms of action. Covers multiple niCBs beyond CBD.
What this study cannot tell us
Review is limited to preclinical data; human clinical evidence for most niCBs in visceral pain is lacking. Animal models of gut pain may not fully translate to human inflammatory bowel disease. The entourage effect concept among niCBs needs rigorous clinical validation.
How to read the evidence
Focused review of preclinical literature with good mechanistic depth, but limited by lack of clinical evidence.
When this study was published
2024 review
The bigger picture
The cannabis plant produces over 100 cannabinoids, most of which are non-intoxicating. Focusing research on the full spectrum of niCBs and their diverse mechanisms could open new therapeutic approaches for gut pain that avoid the psychoactive effects of THC.
Questions still open
- Which specific niCBs are most promising for IBD-related pain? Would targeted niCB formulations outperform whole-plant cannabis for gut conditions? How do TRP channel-mediated effects of niCBs compare to existing pain medications?
Common questions
Can non-intoxicating cannabinoids help with gut pain?
Do I need THC for cannabis to help with abdominal pain?
Read the original research
Non-Intoxicating Cannabinoids in Visceral Pain.
Cannabis and cannabinoid research, 9(1), 3-11
Citation
Svendsen, Kristofer; Sharkey, Keith A; Altier, Christophe. (2024). Non-Intoxicating Cannabinoids in Visceral Pain.. Cannabis and cannabinoid research, 9(1), 3-11. https://doi.org/10.1089/can.2023.0113
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk